European Congress on Obesity 2026 (ECO2026) | News | Updates | 2026 | iPharmaCenter
Novo Nordisk’s Oral Wegovy Shows 21.6% Weight Loss in Early Responders in OASIS 4 Trial Novo Nordisk has reported new clinical data showing that its investigational oral version of Wegovy (semaglutide 25 mg) achieved significant weight loss and functional improvements in adults with obesity. In the OASIS 4 trial, nearly 29% of participants were classified as early responders, defined as achieving at least 10% weight loss by week 16. This group recorded an average weight reduc
UnitedHealthcare Reduces Prior Authorization Requirements by 30% and Standardizes Electronic Submissions | iPharmaCenter
UnitedHealthcare is rolling back prior authorization requirements for a substantial share of its book of business, in a move the company says is aimed at cutting red tape and speeding access to care. The insurer plans to drop prior authorization for 30% of services that previously needed approval and has set a goal to remove an additional 30% of remaining authorizations by the end of 2026, covering categories such as select outpatient surgeries, echocardiograms, outpatient th
Top 10 pharmaceutical companies by revenues in 2026 | Official Figures | iPharmaCenter
Sl No Brand Q1 H1 9M Total 1 Johnson and Johnson $24.0 2 Eli Lilly $19.8 3 Roche $18.8 4 AstraZeneca $15.3 5 Novo Nordisk $15.2 6 AbbVie $15.0 7 Pfizer $14.4 8 Merck $14.3 9 Novartis $13.1 10 Sanofi $12.4 Top pharmaceutical companies by revenues | 2026 JOHNSON AND JOHNSON Q1 REVENUES: In the first quarter of 2026, the company reported total sales of $24.1 billion, reflecting a 9.9% increase. Revenue from Innovative Medicines reached $15.4 billion. Global operational sales in
Digestive Disease Week | 2026 | News | Updates | iPharmaCenter
AbbVie Showcases New Real-World IBD Data for Skyrizi and Rinvoq at DDW 2026 AbbVie’s latest inflammatory bowel disease (IBD) data package from Digestive Disease Week (DDW) 2026 underscores the growing clinical role of Skyrizi (risankizumab) and Rinvoq (upadacitinib) in Crohn’s disease and ulcerative colitis. Real-world results from the ASPIRE-CD study showed that adults with moderately to severely active Crohn’s disease treated with risankizumab achieved rapid and sustained r
Foundayo (orforglipron) Wins FDA Approval as First Anytime GLP‑1 Tablet for Weight Loss | iPharmaCenter
The U.S. FDA has approved Foundayo (orforglipron), a once‑daily GLP‑1 tablet for chronic weight management in adults with obesity or overweight and weight‑related comorbidities. It is currently the only GLP‑1 pill for weight loss that can be taken at any time of day without specific restrictions on food or water intake. Also read: New Hope for GVHD Patients as Rezurock Wins EU Approval Backed by the phase 3 ATTAIN programme, Foundayo delivered clinically meaningful and sustai
New Hope for GVHD Patients as Rezurock Wins EU Approval | iPharmaCenter
The European Commission has granted conditional marketing authorisation for Sanofi’s Rezurock (belumosudil) to treat chronic graft-versus-host disease (GVHD) in adults and adolescents aged 12 years and older who weigh at least 40 kg. The approval offers a critical treatment option for patients who have limited benefit from current therapies or have exhausted existing options. Also read: Top 10 Pharmaceutical Companies by Revenue 2025 The decision is supported by evidence from